21 May 2019
AFT Pharmaceuticals (AFT) today announces it has established a NZ$15 million interim banking facility with the BNZ,
enabling the company to commence refinancing its borrowings at more attractive rates. The new facility uses the existing
security arrangements between AFT, BNZ and CRG.
AFT’s main facility is provided by specialist US-based healthcare investor CRG. The loan attracts an interest rate of
13.5% and matures on 31 March 2020. Although CRG has offered to extend the loan AFT has been exploring options to
refinance its borrowings at more favourable New Zealand commercial lending rates.
The company intends to repay US$9.5 million of the CRG debt in the next few days, significantly reducing its financing
costs. It will continue negotiations with New Zealand commercial banks for a long-term facility which will be used to
repay the balance of the CRG loan on 31 March 2020. Accordingly, the interim BNZ facility expires on 31 March 2020.
AFT Founder and Managing Director Dr Hartley Atkinson said: “We are grateful for the support and financial flexibility
CRG has provided to AFT over five years of significant research and development investment, and as this business matures
it is appropriate for the company to seek alternative borrowing arrangements.”
AFT intends to release its audited results for the 12 Months to 31 March 2019 tomorrow morning at around 9.00am. It is
holding a conference call for media and investors at 10.00am
To attend the conference call please dial in on one of the numbers below at least five minutes before the scheduled call
time, identify yourself to the operator and provide the following confirmation code: 9462706
Australia New Zealand
+61 3 8338 0026 +64 9 887 6907
1800 123 296 0800 452 782
For more information:
Malcolm Tubby Richard Inder
CFO The Project
AFT Pharmaceuticals +64 21 645 643
Tel: +64 9 488 0232
About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of
pharmaceutical products across a wide range of therapeutic categories which are distributed across all major
pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises
both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to
develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to
the rest of the world.